Cirrhosis

🔍 Definition

Cirrhosis is the end-stage result of chronic hepatic injury characterized by diffuse fibrosis, destruction of the normal hepatic parenchymal architecture, and formation of regenerative nodules. It represents a common pathway for many chronic liver diseases and is associated with significant morbidity from portal hypertension, hepatocellular dysfunction, and multiorgan complications, as described by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).

Cirrhosis is classified as compensated (no major complications) or decompensated (presence of ascites, variceal bleeding, hepatic encephalopathy, or jaundice). Decompensated cirrhosis carries a 1-year mortality of approximately 20–57% depending on the degree of organ dysfunction, per AASLD Practice Guidance on Cirrhosis (2021).

MELD-Na Scoring

The Model for End-Stage Liver Disease (MELD) score is the primary prognostic tool for cirrhosis severity and liver transplant prioritization. Since July 13, 2023, OPTN liver allocation for candidates age 12 and older uses MELD 3.0 rather than MELD-Na; MELD 3.0 incorporates bilirubin, creatinine, INR, sodium, albumin, and sex for purposes of allocation. Score ranges remain useful for clinical severity trending: <10 (low near-term mortality), 10–19 (moderate), 20–29 (high), ≥30 (critical/transplant priority).

Child-Pugh Classification

The Child-Pugh score (also Child-Turcotte-Pugh) assesses hepatic reserve using bilirubin, albumin, INR/PT, ascites severity, and degree of encephalopathy. It stratifies patients into Class A (5–6 points; compensated), Class B (7–9 points; significant dysfunction), and Class C (10–15 points; decompensated/end-stage), per MDCalc. Class C carries a 1-year survival of approximately 45%.

🗂️ Alternative Terminology

Coders and CDI specialists will encounter the following terms in clinical documentation that map to cirrhosis codes in ICD-10-CM:

🩺 Signs & Symptoms

Cirrhosis presents across a wide clinical spectrum depending on whether the disease is compensated or decompensated. Clinical signs and symptoms documented in the medical record drive code selection and CDI query opportunities.

Compensated Cirrhosis

• Fatigue, malaise, and weakness
• Spider angiomata and palmar erythema
• Mild hepatomegaly or, later, small nodular liver
• Gynecomastia and testicular atrophy (men)
• Thrombocytopenia (hypersplenism)
• Mildly elevated bilirubin, AST, ALT, alkaline phosphatase

Decompensated Cirrhosis

• Ascites: Abdominal distension, flank dullness, fluid wave; may be complicated by spontaneous bacterial peritonitis (SBP)
• Esophageal/gastric varices: Hematemesis, melena, hematochezia — acute variceal bleeding is a life-threatening emergency
• Hepatic encephalopathy (HE): Confusion, asterixis, altered consciousness ranging from subtle personality changes to coma
• Jaundice: Scleral icterus, skin yellowing, dark urine, pale stools
• Coagulopathy: Easy bruising, prolonged PT/INR, risk of bleeding
• Hepatorenal syndrome (HRS): Progressive azotemia, oliguria in absence of other renal pathology
• Hepatopulmonary syndrome / Portopulmonary hypertension: Dyspnea, hypoxemia
• Sarcopenia and cachexia: Muscle wasting, weight loss, frailty

🧭 Differential Diagnosis

The following conditions may present similarly to cirrhosis or complicate coding decisions when multiple diagnoses are present:

📋 Clinical Indicators

The following clinical indicators in the medical record should prompt code assignment or CDI query initiation for cirrhosis and its complications:

🦴 Anatomy & Pathophysiology

The liver is the largest solid organ, weighing approximately 1,400–1,600 g in adults. It is divided into right and left lobes and receives dual blood supply: the portal vein (~75% of inflow, nutrient-rich from gut) and the hepatic artery (~25%, oxygenated). Blood drains via the hepatic veins into the inferior vena cava, as reviewed in StatPearls: Liver Anatomy (NCBI).

Pathogenesis of Cirrhosis

1. Chronic injury: Repeated hepatocyte damage from alcohol, viral infection (HBV/HCV), metabolic dysfunction (MASLD/NASH), autoimmune processes, cholestasis, or toxins activates hepatic stellate cells (HSCs).
2. Stellate cell activation: Quiescent HSCs transform into myofibroblasts, secreting excess collagen (primarily type I and III) and other extracellular matrix proteins — the hallmark of fibrogenesis.
3. Fibrosis progression: Fibrosis advances from portal (F1) → periportal bridging (F2–F3) → cirrhosis (F4, Metavir scale), replacing normal hepatic architecture with fibrous septa and regenerative nodules per AASLD.
4. Portal hypertension: Disrupted vascular architecture increases intrahepatic resistance → elevated portal pressure; clinically significant portal hypertension (CSPH) is defined by hepatic venous pressure gradient (HVPG) ≥10 mmHg, while HVPG >12 mmHg is associated with risk of variceal bleeding → portosystemic shunting → esophageal/gastric varices, splenomegaly, ascites.
5. Hepatocellular dysfunction: Reduced synthetic capacity manifests as hypoalbuminemia, coagulopathy (reduced clotting factors II, V, VII, IX, X), impaired ammonia metabolism → encephalopathy, hyperbilirubinemia.
6. Systemic inflammation: Bacterial translocation from gut activates systemic immune response, driving SIRS, acute-on-chronic liver failure (ACLF), and multi-organ dysfunction.

Complications Pathophysiology

• Hepatorenal syndrome (HRS): Splanchnic vasodilation → reduced effective circulating volume → renal vasoconstriction → functional renal failure. HRS-AKI (formerly type 1) is rapid; HRS-CKD (formerly type 2) is slower.
• Spontaneous bacterial peritonitis (SBP): Bacterial translocation across gut mucosa into ascitic fluid; most commonly E. coli, Klebsiella, enterococci.
• Hepatic encephalopathy: Ammonia and other gut-derived toxins cross blood-brain barrier due to impaired hepatic clearance and portosystemic shunting; glutamine accumulation in astrocytes → cerebral edema.

💊 Medication Impact / Treatment

Medications used in cirrhosis management directly influence CDI queries, code assignment, and MS-DRG complexity. The following drugs are commonly encountered in cirrhosis-related encounters:

Portal Hypertension / Variceal Prophylaxis

• Non-selective beta-blockers (propranolol, nadolol, carvedilol): First-line primary and secondary prophylaxis for variceal bleeding; documented indication drives K76.6 portal HTN coding query. Per AASLD guidelines, carvedilol is preferred for primary prophylaxis.
• Vasoactive agents: Octreotide is a somatostatin analogue used in acute variceal bleeding management; terlipressin is a vasopressin receptor agonist used for HRS-AKI in appropriate hospitalized adults. IV octreotide commonly initiates at 50 mcg bolus then 25–50 mcg/hr infusion per local protocol.

Ascites Management

• Diuretics (spironolactone ± furosemide): Standard therapy; spironolactone 100 mg + furosemide 40 mg titrated upward per AASLD stepwise protocol.
• Albumin infusion: Used post-large-volume paracentesis (>5 L) to prevent circulatory dysfunction; also used in SBP (1.5 g/kg day 1, 1 g/kg day 3) to reduce HRS risk.
• Tolvaptan: Vasopressin V2 receptor antagonist for hyponatremic ascites; use limited due to hepatotoxicity risk.

Hepatic Encephalopathy

• Lactulose: Reduces ammonia absorption; titrate to 2–3 soft stools/day. Presence in medication record is a CDI trigger for HE documentation.
• Rifaximin (Xifaxan): Non-absorbable antibiotic; reduces gut ammonia-producing bacteria; standard adjunct for recurrent HE. Per FDA prescribing information, indicated for overt HE reduction in adults.
• Zinc supplementation: Zinc deficiency is common in cirrhosis; affects urea cycle.

Infection Prophylaxis / SBP Treatment

• Norfloxacin / ciprofloxacin / trimethoprim-sulfamethoxazole: Long-term SBP prophylaxis in patients with low-protein ascites or prior SBP episode.
• Cefotaxime / ceftriaxone: Empiric treatment for diagnosed SBP.

Anticoagulation Considerations

• Cirrhosis causes a rebalanced coagulation state (both pro- and anticoagulant factors reduced); elevated INR does not reliably indicate bleeding risk. Anticoagulation may be used for portal vein thrombosis (PVT) with LMWH or direct oral anticoagulants per hepatologist guidance.

Liver Transplant Immunosuppression

• Tacrolimus, mycophenolate mofetil, prednisone: Standard post-transplant regimen; ongoing medication requires Z94.4 (liver transplant status) coding in follow-up encounters.

Preview ends here. The full guide continues with FY2026 ICD-10-CM code sets, CPT surgical coding, MS-DRG mapping, reimbursement guidance, CDI query templates, and an audit checklist — all available to CCO Members.

← Back to All Clinical Documentation Guides

📘 ICD-10-CM Guidelines

The following FY 2027 ICD-10-CM official guidelines govern coding of cirrhosis and related hepatic conditions, per CMS FY 2027 ICD-10-CM Official Guidelines for Coding and Reporting:

Etiology-Specificity Requirement

ICD-10-CM requires etiology-specific code selection for cirrhosis. Codes are organized by etiology: alcoholic (K70.3x), toxic/drug-induced (K71.7), biliary (K74.3–K74.5), fibrosis and cirrhosis (K74.0–K74.69). “Cirrhosis NOS” (K74.60) should only be assigned when the provider has not specified an etiology after query. The index directs “Cirrhosis, liver” → K74.60 as default, but coders must verify the medical record for causal documentation.

Combination Codes: Alcoholic Cirrhosis with Ascites

Code K70.30 (Alcoholic cirrhosis of liver without ascites) and K70.31 (Alcoholic cirrhosis of liver with ascites) are combination codes per ICD-10-CM instructions. When a patient with alcoholic cirrhosis has ascites, assign K70.31 — a separate R18.8 ascites code is not needed. However, if SBP complicates the ascites, assign K65.2 additionally.

Chronic Viral Hepatitis with Cirrhosis

When chronic viral hepatitis (B18.x) causes cirrhosis, both the hepatitis code and the cirrhosis code (K74.x) should be assigned per ICD-10-CM convention. The sequencing depends on the reason for the encounter. Example: B18.1 (Chronic hepatitis B without delta-agent) + K74.60 for hepatitis B cirrhosis without further etiologic specificity listed.

Hepatic Failure Codes (K72.x)

Hepatic failure is separately classifiable. When a patient with cirrhosis develops acute-on-chronic hepatic failure, assign the appropriate K72.x code as an additional diagnosis. K72.10 = Chronic hepatic failure without coma; K72.11 = Chronic hepatic failure with coma. Acute hepatic failure (K72.00/K72.01) may be assigned with cirrhosis if documented by the provider.

Hepatic Encephalopathy (HE)

Hepatic encephalopathy NOS or hepatic encephalopathy without coma is classified to K76.82 (Hepatic encephalopathy); code also the underlying liver disease when applicable. Do not assign K76.82 with hepatic failure with coma codes because K76.82 has an Excludes1 note for acute/subacute hepatic failure with coma (K72.01), alcoholic hepatic failure with coma (K70.41), chronic hepatic failure with coma (K72.11), and hepatic failure with coma (K72.91). Query the provider when documentation is unclear regarding coma or the acuity/type of hepatic failure.

Portal Hypertension (K76.6)

Portal hypertension is not automatically included in the cirrhosis code and should be assigned additionally when documented. Code K76.6 may be a significant additional diagnosis impacting MS-DRG assignment.

Hemochromatosis (E83.110)

When hereditary hemochromatosis causes cirrhosis, assign E83.110 (Hereditary hemochromatosis) as the principal code, with the appropriate cirrhosis code as an additional diagnosis, per ICD-10-CM “etiology/manifestation” convention. The metabolic disorder (E83.110) is the etiology; the cirrhosis is the manifestation.

Drug-Induced / Toxic Liver Disease (K71.7)

Code K71.7 (Toxic liver disease with fibrosis and cirrhosis of liver) requires an additional code for the adverse effect (T36–T65 with 7th character A/D/S) or, for underdosing, the appropriate T code. The drug/toxin must be documented by the provider.

🔢 ICD-10-CM Code Set (Tabular)

🔎 Indexing

Use the ICD-10-CM Alphabetic Index under the following lead terms when coding cirrhosis-related conditions. Always verify in the Tabular List per FY 2027 official guidelines:

• Cirrhosis, liver (hepatic) → K74.60 (default); subterms: alcoholic → K70.30; biliary → see Cirrhosis, biliary; with ascites → see subterm of etiology
• Cirrhosis, alcoholic → K70.30 (without ascites), K70.31 (with ascites)
• Cirrhosis, biliary (cholangitic) (hypertrophic) (obstructive) (pericholangiolitic) → K74.5; primary → K74.3; secondary → K74.4
• Cirrhosis, NASH → K74.69 (index may direct to “other” cirrhosis)
• Cirrhosis, cardiac → K74.69
• Fibrosis, hepatic → K74.00 when unspecified; early/stage F1 → K74.01; moderate/stage F2 → K74.0A; advanced/bridging/stage F3 → K74.02; with sclerosis → K74.2
• Encephalopathy, hepatic → K76.82 (code also underlying liver disease when applicable; see Excludes1 for hepatic failure with coma codes)
• Failure, hepatic, chronic → K72.10 (without coma), K72.11 (with coma)
• Hypertension, portal → K76.6
• Syndrome, hepatorenal → K76.7
• Varices, esophageal → I85.00 (without bleeding), I85.01 (with bleeding)
• Peritonitis, spontaneous bacterial → K65.2
• Ascites → R18.0 (malignant), R18.8 (other)
• Hemochromatosis, hereditary → E83.110

🏥 CPT

The following CPT codes apply to procedures commonly performed for cirrhosis and its complications. Verify modifier applicability and payer-specific requirements per AMA CPT 2027:

🧾 HCPCS

📚 AHA Coding Clinic

The following AHA Coding Clinic advisories are particularly relevant to cirrhosis coding. Coders and CDI specialists should reference the Coding Clinic database for the most current guidance:

• Coding Clinic guidance on Hepatic Encephalopathy: When a patient with cirrhosis is admitted with altered mental status and the provider documents hepatic encephalopathy without coma or hepatic encephalopathy NOS, assign K76.82 in addition to the underlying liver disease code. If the provider documents hepatic failure with coma, assign the appropriate hepatic failure-with-coma code instead of K76.82 because K76.82 has an Excludes1 note for hepatic failure with coma codes. Coders should not infer coma from a GCS score alone.
• Acute-on-Chronic Liver Failure (ACLF): Coding Clinic has advised that ACLF should be coded as acute hepatic failure (K72.00/K72.01) when explicitly documented by the provider as an acute deterioration superimposed on chronic liver disease. Query if documentation uses only the term “ACLF” without further specification.
• NASH/MASLD Cirrhosis: Coding Clinic has advised that NASH cirrhosis and nonalcoholic fatty liver disease (NAFLD)-related cirrhosis are classified to K74.69 (Other cirrhosis of liver), not K74.60. The ICD-10-CM Alphabetic Index does not have a specific entry for NASH cirrhosis, but K74.69 is the appropriate code per official guidance.
• SBP Coding: When spontaneous bacterial peritonitis is documented in a patient with ascites and cirrhosis, assign K65.2 (SBP) as an additional code. The ascites is captured either in the cirrhosis combination code (K70.31) or separately (R18.8) depending on etiology.
• Hepatorenal Syndrome types: When the provider documents HRS type 1 (now HRS-AKI) or HRS type 2 (now HRS-CKD), both map to K76.7 in FY2026 ICD-10-CM. There is no separate code distinguishing type 1 from type 2 at this time. An additional code for the acute kidney injury (N17.x) may also be appropriate when AKI criteria are met and documented.
• Portal Hypertension: Coding Clinic confirms that portal hypertension (K76.6) is not inherent to the cirrhosis codes and should be assigned additionally when documented. Do not assume portal HTN from the presence of varices alone — provider documentation is required.

💰 HCC / Risk Adjustment

Under the CMS-HCC Model v28 (effective for payment year 2024 onward and fully implemented for payment year 2026), liver disease categories were renumbered from the v24 HCC 27/28/29 structure to v28 HCC 62, 63, 64, 65, and 68. Cirrhosis, chronic liver failure/end-stage liver disorders, chronic hepatitis, cholangitis/obstruction diagnoses, and liver transplant status/complications map to distinct hierarchical condition categories that significantly impact risk-adjusted payment for Medicare Advantage plans:

MS-DRG Mapping (Inpatient)

For inpatient encounters, cirrhosis-related MS-DRGs under FY2026 include:

• DRG 432: Cirrhosis and alcoholic hepatitis with MCC
• DRG 433: Cirrhosis and alcoholic hepatitis with CC
• DRG 434: Cirrhosis and alcoholic hepatitis without CC/MCC
• DRG 682–684: Renal failure (when HRS/AKI is principal diagnosis)
• DRG 405–407: Pancreas, liver, and shunt procedures (when TIPS or liver biopsy drives the DRG)

MCC codes (K70.31, K72.10/11, K76.7, I85.01, K65.2) can shift DRG assignment from 443 (lowest weight) to 441 (highest weight), significantly impacting reimbursement. Accurate documentation of ALL complications is essential.

✍️ CDI Query Templates

All query templates below conform to AHIMA/ACDIS CDI Query Practice Brief (2019) standards: non-leading, multiple-choice format, based on clinical indicators present in the record, and directed to the treating/attending provider.

🧑‍⚕️ Treatments (Clinical)

The following summarizes evidence-based clinical treatments for cirrhosis and its complications per AASLD Practice Guidance on Cirrhosis and ACG guidelines:

General Management

• Etiology treatment: Alcohol abstinence (alcoholic cirrhosis), antiviral therapy for HBV/HCV, weight loss/metabolic management for MASLD, immunosuppression for autoimmune hepatitis
• Nutritional support: Protein intake 1.2–1.5 g/kg/day; late-evening snack; avoid prolonged fasting; branched-chain amino acids if protein-intolerant
• Vaccination: Hepatitis A, hepatitis B, influenza, pneumococcal, COVID-19 vaccines recommended for all cirrhotics
• Surveillance: Biannual liver ultrasound ± AFP for hepatocellular carcinoma surveillance per AASLD HCC Surveillance Guidelines

Ascites

• Sodium restriction (2 g/day) and diuretics (spironolactone ± furosemide)
• Large-volume paracentesis (LVP) for refractory or tense ascites with albumin infusion (6–8 g/L removed)
• TIPS for refractory ascites when LVP >3/month and preserved liver function

Variceal Bleeding

• Primary prophylaxis: Non-selective beta-blockers (carvedilol preferred) or endoscopic variceal ligation (EVL)
• Acute bleeding: IV octreotide + EVL (endoscopic band ligation) within 12 hours of presentation; antibiotic prophylaxis (ceftriaxone 1 g IV for 7 days)
• TIPS: Salvage therapy for failed endoscopic treatment; early TIPS (within 72 hours) in Child-Pugh C patients
• Secondary prophylaxis: Beta-blocker + EVL combination therapy

Hepatic Encephalopathy

• Identify and treat precipitants (infection, GI bleed, constipation, electrolyte imbalance, medications)
• Lactulose titrated to 2–3 soft stools/day
• Rifaximin 550 mg twice daily for recurrent HE prevention
• Dietary protein modification (avoid excessive restriction)

Spontaneous Bacterial Peritonitis

• Cefotaxime 2 g IV q8h × 5 days (or ceftriaxone); IV albumin 1.5 g/kg on day 1, 1 g/kg on day 3 to prevent HRS
• Long-term norfloxacin prophylaxis after first SBP episode

Hepatorenal Syndrome

• HRS-AKI: IV albumin for volume expansion plus vasoconstrictor therapy when diagnostic criteria are met; terlipressin is preferred when appropriate, norepinephrine is an alternative and may be preferred in shock, and midodrine + octreotide may be considered only when terlipressin and norepinephrine cannot be used because efficacy is low.
• Terlipressin (approved by FDA 2022 for HRS-AKI) as first-line in appropriate patients
• Renal replacement therapy as bridge to liver transplant

Liver Transplantation

• Definitive treatment for end-stage cirrhosis; MELD-Na ≥ 15 typically triggers evaluation
• Evaluation includes cardiac, pulmonary, psychosocial, and substance use assessment
• Post-transplant 1-year survival exceeds 90% at experienced centers per OPTN national data

🎓 Patient Education / Summary

For coders and CDI specialists preparing patient-facing summaries or coordinating with care teams, the following key patient education points are relevant to documentation accuracy and care coordination:

What Is Cirrhosis?

Cirrhosis means the liver has developed permanent scarring (fibrosis) that prevents it from working normally. It is the end result of many years of liver injury from alcohol, hepatitis viruses, fat buildup, or other causes. The liver cannot regenerate once cirrhosis is established, but treating the underlying cause and managing complications can significantly slow progression and improve quality of life, per NIDDK Cirrhosis patient information.

Warning Signs Requiring Immediate Attention

• Vomiting blood or black/tarry stools: May indicate variceal bleeding — call 911 immediately
• Severe confusion, excessive sleepiness, or inability to wake: May indicate hepatic encephalopathy — seek emergency care
• Fever with abdominal pain in the setting of known ascites: May indicate spontaneous bacterial peritonitis (SBP)
• Markedly decreased urine output with swelling: May indicate hepatorenal syndrome

Lifestyle and Self-Management

• Complete alcohol abstinence for all patients with cirrhosis, regardless of etiology
• Low-sodium diet (2,000 mg/day or less) to manage ascites
• Medication adherence: Never stop diuretics, beta-blockers, or lactulose without provider guidance
• Avoid NSAIDs (ibuprofen, naproxen) — these can precipitate renal failure in cirrhosis
• Avoid sedatives and opioids unless prescribed — these can precipitate hepatic encephalopathy
• Regular follow-up appointments for surveillance ultrasound, endoscopy, and lab work

Coding and Documentation Summary for CDI Teams

• Always document etiology of cirrhosis (alcoholic, NASH, viral, biliary, cryptogenic, etc.)
• Document all active complications: ascites, encephalopathy, varices (with/without bleeding), SBP, HRS
• Document MELD-Na score and Child-Pugh class in H&P for severity substantiation
• Record acuity of hepatic failure when present (acute, chronic, acute-on-chronic)
• For HRS, specify type (HRS-AKI vs. HRS-CKD) to support coding and clinical management
• Document transplant evaluation status or active waitlist status when applicable

For additional patient resources, refer patients to the American Liver Foundation – Cirrhosis Information and NIDDK Cirrhosis Patient Guide.

About this Guide

This Clinical Documentation Guide is published by CCO Academy and is intended for credentialed coding, CDI, and clinical documentation professionals. Content is updated for FY 2027 ICD-10-CM (effective October 1, 2026) and CPT/HCPCS 2027 (effective January 1, 2027). All code assignments should be verified against the official ICD-10-CM Tabular List, AHA Coding Clinic, AMA CPT, HCPCS Level II, NCCI, and applicable payer-specific policies. This guide does not constitute legal, medical, or compliance advice.

Last reviewed: April 2026 · Next scheduled review: October 2026 (FY2027 update)